Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPO: Point-of-care HCV Testing and Treatment in PWID
NCT03492112Completed
- Sponsor
- The Kirby Institute
- Start
- Sep 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sofosbuvir + velpatasvir and glecaprevir + pibrentasvir in hepatitis C (HCV), sponsored by The Kirby Institute. Primary endpoint: Uptake of HCV DAA therapy among current PWID at 4 weeks. Started Sep 2019; status: completed.
02
Drugs
sofosbuvir + velpatasvirglecaprevir + pibrentasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03492112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492112.